Skip to main content

Table 2 Associations of plasma biomarkers with NPS severity and NPS severity change

From: Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression

 

baseline NPS

future NPS

NPS severity change

OR (95% CI)

p

OR (95% CI)

p

β (95% CI)

p

NfL

1.1 (0.8–1.6)

0.590

1.6 (1.0–2.7)

0.068

0.25 (0.02–0.48)

0.034*

GFAP

1.2 (0.8–1.8)

0.330

2.8 (1.5–5.2)

0.002*

0.30 (0.07–0.55)

0.013*

pTau181

1.2 (0.8–1.7)

0.319

1.3 (0.8–1.9)

0.267

0.06 (-0.14–0.26)

0.542

  1. Description: Results from the linear regression analysis showing the associations of plasma NfL, GFAP and pTau181 with NPS severity at baseline and follow-up (based on the NPI-Q total severity score) as well as the NPS severity change over time (defined through the ∆NPI-Q total severity score between baseline and follow-up) after considering age and sex. Beta coefficients, 95% confidence interval and p-values are shown. GFAP, glial fibrillary acid protein; NfL, neurofilament light chain; NPI-Q, neuropsychiatric inventory questionnaire; NPS, neuropsychiatric symptoms; pTau181, tau phosphorylated at threonine 181
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193